Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC By Ogkologos - July 14, 2025 763 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Kid Friendly Meals October 2, 2020 FDA Approves Azacitidine Tablets for Acute Myeloid Leukaemia September 4, 2020 EMA Issues Direct Healthcare Professional Communications for Crizotinib-Related Vision Disorders in... June 24, 2022 Ovarian Cancer Studies Aim to Reduce Racial Disparities, Improve Outcomes July 16, 2020 Load more HOT NEWS FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection Mom Gives ‘Elf On The Shelf’ A Wheelchair For Daughter With... Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients... FDA Approves Blood Tests That Can Help Guide Cancer Treatment
